Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Trading Up 2.5 %

Shares of Evogene stock opened at $1.42 on Friday. The firm has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $2.24. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40. The stock has a market capitalization of $7.60 million, a price-to-earnings ratio of -0.32 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent quarter. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.